

Solid Tumors

A study to see how the cancer medicine pralsetinib interacts with other common medicines and birth control pills

A study to evaluate the drug-drug interaction potential of pralsetinib in combination with substrates of various transporters or CYP enzymes or a combined oral contraceptive in participants with advanced or metastatic solid tumors that are not responsive to standard therapies

Trial Status
Completed

Trial Runs In
2 Countries

Trial Identifier
ISRCTN14442671 2022-001557-23
GP43164

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

Trial Summary:

ISRCTN14442671 2022-001557-23 GP43164
Trial Identifiers

Eligibility Criteria:

Gender

Age

Healthy Volunteers
